adamantane has been researched along with Insulin Sensitivity in 67 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (14.93) | 29.6817 |
2010's | 54 (80.60) | 24.3611 |
2020's | 3 (4.48) | 2.80 |
Authors | Studies |
---|---|
Coskun, ZM | 1 |
Abdel-Aal, RA; Abdel-Rahman, MS; Al Bayoumi, S; Ali, LA | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Saiyasit, N; Sripetchwandee, J | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jiang, C; Li, X; Liang, G; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
Chen, Q; Huang, L; Kong, L; Wang, J; Wang, Z; Xu, D; Zhang, T; Zhou, X | 1 |
Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P | 1 |
Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H | 1 |
Li, M; Ping, F; Wang, T; Wang, X; Xiao, X; Yu, M; Zhang, Q; Zheng, J | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, S; Ittichaicharoen, J; Sa-Nguanmoo, P; Tanajak, P | 1 |
Bolkent, S; Coskun, ZM; Nephan, G | 1 |
Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jiang, C; Kerdphoo, S; Li, X; Liang, G; Pratchayasakul, W; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
Chen, K; Mei, Q; Wang, J; Zhuo, T | 1 |
Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L | 1 |
Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 3 |
Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA | 1 |
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD | 2 |
Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS | 1 |
Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 2 |
Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
Chen, H; Chen, R; Liu, Y; Sun, J; Zhang, Z | 1 |
Horie, A; Ide, K; Ishizuka, T; Kanatsuka, A; Marumo, K; Oshikiri, K; Sunaga, M; Suzuki, Y; Tokuyama, Y | 1 |
Choi, SA; Jang, JY; Jung, HS; Kim, HC; Kim, JH; Kim, MJ; Kim, SW; Lee, HM; Lee, KB; Ohn, JH; Park, KS; Yoon, JW | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S | 1 |
Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Pratchayasakul, W; Sripetchwandee, J | 1 |
Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pongkan, W; Pratchayasakul, W | 1 |
Fan, X; Fan, Y; Li, X; Ren, F; Ren, G; Shen, C; Shen, J; Song, Y; Yang, J; Zhang, N; Zhang, Y; Zheng, H | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC | 1 |
Choi, CS; Han, HY; Jeong, KH; Jun, HS; Kim, S; Kim, SS; Lee, HJ; Oh, H; Ryu, JH; Sa, JH; Son, HJ | 1 |
Brückner, J; Eckel, J; Röhrborn, D; Sell, H | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Inthachai, T; Lekawanvijit, S | 1 |
Amblee, A; Fogelfeld, L; Lious, D | 1 |
Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sa-Nguanmoo, P; Sivasinprasasn, S | 1 |
Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kredphoo, S; Pintana, H; Pongkan, W; Sivasinprasasn, S | 1 |
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Khamseekaew, J; Pintana, H; Siri-Angkul, N; Tanajak, P | 1 |
Abdallah, DM; Al-Shorbagy, MY; Aldakinah, AA; El-Abhar, HS | 1 |
Chattipakorn, N; Chattipakorn, SC; Pongkan, W; Pratchayasakul, W; Sivasinprasasn, S; Tanajak, P | 1 |
Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A | 1 |
Barnett, AH; Piya, MK; Tahrani, AA | 1 |
Aerts, JM; Arbeeny, C; Aten, J; Bijl, N; Dubbelhuis, PF; Ghauharali-van der Vlugt, K; Groen, AK; Ottenhoff, R; Overkleeft, HS; Seeman, I; van Eijk, M; van Roomen, CP | 1 |
Aerts, JM; Aten, J; Bijl, N; Boot, RG; Claessen, N; Groen, AK; Langeveld, M; Moerland, PD; Ottenhoff, R; Sokolović, M; van Eijk, M; van Roomen, CP; Vrins, C | 1 |
Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
Foley, JE; Jordan, J | 1 |
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 3 |
Ito, H; Mimori, N; Sekiguchi, K; Wajima, T; Yamaguchi, M | 1 |
Aavula, BR; Anandan, SK; Cases, S; Chen, D; Cheng, Y; Do, ZN; Gless, R; Hammock, BD; Jones, PD; MacIntyre, DE; Mehra, U; Patel, DV; Sabry, J; Tran, V; Vincelette, J; Wang, YX; Waszczuk, J; Webb, HK; Whitcomb, R; White, K; Wong, KR; Zhang, LN | 1 |
Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
Dotta, F; Fondelli, C; Guarino, E; Nigi, L; Patti, A | 1 |
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
Ahn, JH; Jung, WH; Kang, NS; Kang, SK; Kim, HY; Kim, KY; Park, JS; Rhee, SD | 1 |
Nakamura, A; Terauchi, Y | 1 |
Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pipatpiboon, N; Pratchayasakul, W | 1 |
Balkan, B; Bolognese, L; Burkey, BF; Hughes, TE; Li, X; Mone, M; Russell, M; Wang, PR | 1 |
Balkovec, JM; Chen, HY; Cheng, K; Hermanowski-Vosatka, A; Hernandez, M; Koo, GC; Le Grand, CB; Li, Z; Metzger, JM; Mundt, SS; Noonan, H; Nunes, CN; Olson, SH; Pikounis, B; Ren, N; Robertson, N; Schaeffer, JM; Shah, K; Springer, MS; Strack, AM; Strowski, M; Thieringer, R; Wright, SD; Wu, K; Wu, T; Xiao, J; Zhang, BB | 1 |
Winkler, G | 1 |
Göke, B | 1 |
Ahrén, B; Foley, JE | 1 |
7 review(s) available for adamantane and Insulin Sensitivity
Article | Year |
---|---|
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Vildagliptin; Weight Gain | 2010 |
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Nitriles; Pyrrolidines; Tablets; Treatment Outcome; Vildagliptin | 2012 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastric Emptying; Glucagon-Like Peptide 1; Glucose; Humans; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
13 trial(s) available for adamantane and Insulin Sensitivity
Article | Year |
---|---|
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose Intolerance; Homeostasis; Humans; Insulin Resistance; Life Style; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Prediabetic State; Treatment Outcome | 2017 |
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Topics: Acarbose; Adamantane; Aged; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Type 2; Dipeptides; DNA-Binding Proteins; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Male; Metabolome; Metformin; Middle Aged; Nerve Tissue Proteins; Nucleobindins; Up-Regulation | 2018 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain | 2019 |
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index | 2013 |
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Topics: Adamantane; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; GPI-Linked Proteins; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lectins; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Nitriles; Pyrrolidines; Serpins; Vildagliptin | 2013 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; HMGB1 Protein; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans Transplantation; Male; Metformin; Middle Aged; Nitriles; Pancreatectomy; Pancreatic Neoplasms; Pyrrolidines; Transplantation, Autologous; Vascular Endothelial Growth Factor A; Vildagliptin | 2015 |
Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vildagliptin | 2010 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss | 2012 |
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Topics: Adamantane; Adult; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Intention to Treat Analysis; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Resistin; Retinol-Binding Proteins, Plasma; Vildagliptin | 2012 |
47 other study(ies) available for adamantane and Insulin Sensitivity
Article | Year |
---|---|
ER Stress Amelioration by Saxagliptin Protects the Liver Against Fructose-induced Insulin Resistance.
Topics: Adamantane; Animals; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fructose; Humans; Insulin Resistance; Liver; Male; Rats | 2020 |
Effect of stevia aqueous extract on the antidiabetic activity of saxagliptin in diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptides; Herb-Drug Interactions; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Niacinamide; Plant Extracts; Rats; Rats, Wistar; Stevia; Streptozocin | 2021 |
Neurotensin receptor 1 agonist provides neuroprotection in pre-diabetic rats.
Topics: Adamantane; Animals; Cognitive Dysfunction; Diet, High-Fat; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hippocampus; Ileum; Imidazoles; Insulin Resistance; Male; Neuronal Plasticity; Obesity; Oligopeptides; Oxidative Stress; Prediabetic State; Random Allocation; Rats, Wistar; Receptors, Neurotensin | 2021 |
Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diabetic Cardiomyopathies; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Gene Expression Regulation; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mitochondria, Heart; Nitriles; Obesity; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Vildagliptin | 2017 |
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Apoptosis; Benzhydryl Compounds; Brain; Cognition Disorders; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Insulin; Insulin Resistance; Long-Term Potentiation; Male; Malondialdehyde; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neuroprotective Agents; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2017 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Resistance; Locomotion; Male; Metformin; Nerve Tissue Proteins; Oxidative Stress; Rats; Rats, Wistar; Reaction Time | 2017 |
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
Topics: Adamantane; Administration, Oral; Animals; Blood Glucose; Butyrates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Insulin Resistance; Interleukin-6; Male; Nitriles; Pyrrolidines; Random Allocation; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Vildagliptin | 2017 |
Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Topics: Adamantane; Animals; Apoptosis; Blotting, Western; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Inflammation; Insulin Resistance; Male; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Salivary Glands; Vildagliptin | 2018 |
Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance.
Topics: Adamantane; Animals; Apoptosis; Dietary Carbohydrates; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Insulin Resistance; Male; Pancreas; Rats; Rats, Sprague-Dawley | 2018 |
FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats.
Topics: Adamantane; Animals; Apoptosis; Cognitive Dysfunction; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Hippocampus; Humans; Insulin Resistance; Male; Malondialdehyde; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats, Wistar; Signal Transduction; Vildagliptin | 2018 |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phosphatidylcholines; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
[Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes].
Topics: Adamantane; Animals; bcl-2-Associated X Protein; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Disease Models, Animal; Hepatocytes; Insulin Resistance; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley | 2014 |
The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance.
Topics: Adamantane; Area Under Curve; C-Reactive Protein; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Heart Rate; Insulin Resistance; Intracellular Space; Male; Metformin; Mitochondria; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitriles; Obesity; Pyrrolidines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Vildagliptin | 2014 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Cholesterol; Dendritic Spines; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Neuroprotective Agents; Nitriles; Obesity; Pioglitazone; PPAR gamma; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Thiazolidinediones; Vildagliptin | 2014 |
Dipeptidyl peptidase 4 inhibitor improves brain insulin sensitivity, but fails to prevent cognitive impairment in orchiectomy obese rats.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Insulin Resistance; Male; Maze Learning; Mitochondria; Neuronal Plasticity; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2015 |
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Apelin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Time Factors; Treatment Outcome; Up-Regulation; Vildagliptin | 2015 |
Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Nitriles; Obesity; Oxidative Stress; Pyrrolidines; Rats; Sitagliptin Phosphate; Ventricular Function, Left; Vildagliptin | 2016 |
A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Body Weight; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glycated Hemoglobin; Insulin Resistance; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrimidines | 2015 |
Reduced DPP4 activity improves insulin signaling in primary human adipocytes.
Topics: Adamantane; Adipocytes; Cell Differentiation; Cells, Cultured; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Signal Transduction; Sitagliptin Phosphate | 2016 |
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enalapril; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Myocardial Infarction; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling; Vildagliptin | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estrogens; Female; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Menopause, Premature; Metformin; Mitochondria, Heart; Nitriles; Obesity; Ovariectomy; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2016 |
Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats.
Topics: Adamantane; Androgens; Animals; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Heart; Heart Rate; Insulin Resistance; Male; Mitochondria, Heart; Myocardial Reperfusion Injury; Nitriles; Obesity; Orchiectomy; Pyrrolidines; Rats; Rats, Wistar; Testosterone; Ventricular Function, Left; Vildagliptin | 2016 |
Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Caloric Restriction; Cardiotonic Agents; Diet, High-Fat; Fibroblast Growth Factors; Heart Rate; Insulin Resistance; Intra-Abdominal Fat; Male; Mitochondria, Heart; Nitriles; Oxidative Stress; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Ventricular Function, Left; Vildagliptin | 2017 |
Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway.
Topics: Adamantane; Alkaloids; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipids; Male; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Signal Transduction; Vildagliptin | 2017 |
DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.
Topics: Adamantane; Animals; Apoptosis; Blood Glucose; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estradiol; Fasting; Female; Heart Rate; Insulin Resistance; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Nitriles; Obesity; Ovariectomy; Pyrrolidines; Rats; Rats, Wistar; Stroke Volume; Ventricular Function, Left; Vildagliptin | 2017 |
Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipogenesis; Adiponectin; Adipose Tissue; Animals; Chemokine CCL2; Glucose; Glycosphingolipids; Homeostasis; Inflammation; Insulin Resistance; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Signal Transduction | 2009 |
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Disease Models, Animal; Fatty Liver; Glucose; Glycosphingolipids; Homeostasis; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Triglycerides | 2009 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Topics: Adamantane; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin Resistance; Mice; Obesity; Rats; Urea | 2011 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2012 |
Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adipocytes; Adipogenesis; Adrenal Glands; Animals; Biomarkers; CHO Cells; Cricetinae; Cricetulus; Diet; Enzyme Inhibitors; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Insulin Resistance; Mice; Molecular Docking Simulation; Obesity; Protein Conformation; Thiadiazines | 2012 |
Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes.
Topics: Adamantane; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2013 |
DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption.
Topics: Adamantane; Animals; Brain; Cognition; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucagon-Like Peptide 1; Insulin Receptor Substrate Proteins; Insulin Resistance; Long-Term Synaptic Depression; Male; Maze Learning; Membrane Potential, Mitochondrial; Memory; Mitochondria; Neurons; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrrolidines; Rats; Rats, Wistar; Receptor, Insulin; Vildagliptin | 2013 |
Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Topics: Adamantane; Animals; Area Under Curve; Blood Glucose; Dietary Fats; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Oxidase; Glucose Tolerance Test; Insulin Resistance; Male; Nitriles; Pyrrolidines; Rats; Rats, Zucker; Tachyphylaxis; Time Factors; Vildagliptin; Weight Gain | 2005 |
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Aorta; Arteriosclerosis; Azepines; Blood Glucose; Cortisone; Diet, Atherogenic; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Fatty Acids; Hydrocortisone; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Syndrome; Triazoles; Triglycerides | 2005 |
Molecule of the month. Vildagilptin.
Topics: Adamantane; Diabetes Mellitus; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2006 |
Islet cell function is as interesting as insulin resistance for T2DM treatment options.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Insulin Resistance; Islets of Langerhans; Nitriles; Pyrrolidines; Vildagliptin | 2008 |